Translating Benzodiazepine Utilization Data into Meaningful Population Exposure: Integration of Two Metrics for Improved Reporting
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Drug utilization research on benzodiazepines remains important for measuring trends in consumption within and across borders over time for the sake of monitoring prescribing patterns and identifying potential population safety concerns. The defined daily dose (DDD) system by the World Health Organization (WHO) remains the internationally accepted standard for measuring drug consumption; however, beyond consumption, DDD-based results are difficult to interpret when individual agents are compared with one another or are pooled into a total class-based estimate. The diazepam milligram equivalent (DME) system provides approximate conversions between benzodiazepines and Z-drugs (i.e. zopiclone, zolpidem, zaleplon) based on their pharmacologic potency. Despite this, conversion of total dispensed benzodiazepine quantities into DME values retains diazepam milligrams as the total unit of measurement, which is also impractical for population-level interpretation. In this paper, we propose the use of an integrated DME-DDD metric to obviate the limitations encountered when the component metrics are used in isolation. Through a case example, we demonstrate significant change in results between the DDD and DME-DDD method. Unlike the DDD method, the integrated DME-DDD metric offers estimation of population pharmacologic exposure, and enables superior interpretation of drug utilization results, especially for drug class summary reporting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, accurate benzodiazepine conversion (i.e diazepam milligram equivalence) for individual patients still remain a challenge that may be improved upon by further research.168”
Citations
Cites
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
The diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455
Brandt, J., & Leong, C. (2017) · Drugs in R&D · doi:10.1007/s40268-017-0207-7 · Cited by 356
Self-citationManagement of benzodiazepine misuse and dependence
Brett, J., & Murnion, B. (2015) · Australian Prescriber · doi:10.18773/austprescr.2015.055 · Cited by 260
Svendsen, K., Borchgrevink, P., Fredheim, O., Hamunen, K., Mellbye, A., & Dale, O. (2011) · Palliative Medicine · doi:10.1177/0269216311398300 · Cited by 206
The Benzodiazepine–Dementia Disorders Link: Current State of Knowledge
Pariente, A., de Gage, S. B., Moore, N. D., & Bégaud, B. (2015) · CNS Drugs · doi:10.1007/s40263-015-0305-4 · Cited by 144
Comparison of dose standard units for drug utilisation studies
Merlo, J., Wessling, A., & Melander, A. (1996) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050064 · Cited by 131
Biomarkers for the effects of benzodiazepines in healthy volunteers
De Visser, S. J., Van Der Post, J. P., De Waal, P. P., Cornet, F., Cohen, A. F., & Van Gerven, J. M. A. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.t01-10-01714.x · Cited by 114
Lack of Relationship Between Long-Term Use of Benzodiazepines and Escalation to High Dosages
Soumerai, S. B., Simoni-Wastila, L., Singer, C., Mah, C., Gao, X., Salzman, C., & Ross-Degnan, D. (2003) · Psychiatric Services · doi:10.1176/appi.ps.54.7.1006 · Cited by 104
Is the Defined Daily Dose system a reliable tool for standardizing antipsychotic dosages?
Nosè, M., Tansella, M., Thornicroft, G., Schene, A., Becker, T., Veronese, A., Leese, M., Koeter, M., Angermeyer, M., & Barbui, C. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328303ac75 · Cited by 83
Twenty‐year trends in benzodiazepine dispensing in the Australian population
Islam, M. M., Conigrave, K. M., Day, C. A., Nguyen, Y., & Haber, P. S. (2014) · Internal Medicine Journal · doi:10.1111/imj.12315 · Cited by 73
What is the point of guidelines? Benzodiazepine and z-hypnotic use by an elderly population
Neutel, C. I., Skurtveit, S. O., & Berg, C. (2012) · Sleep Medicine · doi:10.1016/j.sleep.2011.12.014 · Cited by 72
Discrepancies between prescribed and defined daily doses: a matter of patients or drug classes?
Grimmsmann, T., & Himmel, W. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1014-7 · Cited by 66
Meta-Analyses of Hypnotics and Infections: Eszopiclone, Ramelteon, Zaleplon, and Zolpidem
Joya, F. L., Kripke, D. F., Loving, R. T., Dawson, A., & Kline, L. E. (2009) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.27552 · Cited by 62
The crucial question of standardisation when measuring drug consumption
Chauvin, C., Madec, F., Guillemot, D., & Sandérs, P. (2001) · Veterinary Research · doi:10.1051/vetres:2001145 · Cited by 60
Use of benzodiazepine and risk of cancer: A meta-analysis of observational studies
Kim, H.-B., Myung, S.-K., Park, Y. C., & Park, B. (2017) · International Journal of Cancer · doi:10.1002/ijc.30443 · Cited by 43
Trends in the prescription of benzodiazepines for the elderly in Korea
Hwang, S.-H., Han, S. J., Choi, H.-J., Park, C.-S., Kim, S. M., & Kim, T. H. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1467-z · Cited by 40
Sustained Use of Benzodiazepines and Escalation to High Doses in a Canadian Population
Alessi‐Severini, S., Bolton, J. M., Enns, M. W., Dahl, M. E., Chateau, D. G., Collins, D. M., & Sareen, J. (2016) · Psychiatric Services · doi:10.1176/appi.ps.201500380 · Cited by 38
Sweileh, W. M., Odeh, J. B., Shraim, N. Y., Zyoud, S. H., Sawalha, A. F., & Al‐Jabi, S. W. (2013) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2013.03.003 · Cited by 35
A Comparison of Benzodiazepine and Related Drug Use in Nova Scotia and Australia
Smith, A. J., SKETRIS, I. S., Cooke, C., Gardner, D. M., Kisely, S. R., & Tett, S. E. (2008) · The Canadian Journal of Psychiatry · doi:10.1177/070674370805300809 · Cited by 28
Benzodiazepines utilization and self‐medication as correlates of stress in the population of Serbia
Divac, N., Jašović, M., Djukić, L., Vujnović, M., Babić, D., Bajčetić, M., & Samardžić, R. (2004) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.940 · Cited by 28
Strand, M. C., Mørland, J. G., Slørdal, L., Riedel, B., Innerdal, C., Aamo, T. O., Mathisrud, G., & Vindenes, V. (2017) · Forensic Science International · doi:10.1016/j.forsciint.2017.10.022 · Cited by 24
Trends in utilization of benzodiazepine and Z‐drugs in Israel
Berman, E., Eyal, S., & Marom, E. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4338 · Cited by 20
[Benzodiazepine's utilization in continental Portugal (1999-2003)].
Furtado, C. D., & Teixeira, I. (2007) · PubMed · Cited by 14
Liaw, G.-W., Hung, D., Chen, W.-K., Lin, C., Lin, I., & Kao, C. (2015) · Medicine · doi:10.1097/md.0000000000002376 · Cited by 14
Busse, J. W., Juurlink, D. N., Buckley, D. N., & Guyatt, G. H. (2017) · Canadian Medical Association Journal · doi:10.1503/cmaj.733313 · Cited by 12
Shader, R. I., & Greenblatt, D. J. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199708000-00024 · Cited by 11
Guo, Z., Feng, L., Yan, X., Yang, L., Huang, S., Xing, Y., & Yang, Y. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1428-6 · Cited by 8
Jørgensen, V. R. K. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.03.008 · Cited by 2
Research works printed but not linked: 1
- Stein MB, Goin MK, Pollack HM, Roy-Byrne P, Sareen J, Campbell-Sills L. Practice guideline for the Treatment of Patients With Panic Disorder. Am Psychiatr Assoc. 2010;2:1–90.
Cited by
Brandt, J., Bressi, J., Lê, M.-L., Neal, D., Cadogan, C., Witt-Doerring, J., Witt-Doerring, M., & Wright, S. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102507 · Cited by 77
“168 Another area of contention in the prescriptive management of BZD withdrawal is the use of alternative pharmacotherapies as either adjuncts or to substitute the BZD entirely.”
BackgroundSelf-citationBrandt, J., Alessi‐Severini, S., Singer, A. G., & Leong, C. (2019) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.22374/1710-6222.26.1.3 · Cited by 46
Gong, W., Zhai, Q., Wang, Y., Shen, A., Huang, Y., Shi, K., Huang, Y., Song, M., Yan, R., Yao, Z., et al. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.04.008 · Cited by 35
Gale, C. K., Glue, P., Guaiana, G., Coverdale, J., McMurdo, M., & Wilkinson, S. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881118822146 · Cited by 26
Liu, L., Jian, P., Zhou, Y., Zhou, J. H., Jia, L., Tang, M., Zhang, R., & Tang, Y. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595623 · Cited by 31
“Based on the self-report medication history obtained in the interviews and prescription record in the electronic medical record system, we converted the accumulated BZD dosage and average daily BZD dosage of each participant into diazepam equivalents (27).”
Method
Metadata
- Authors
- Brandt, J., Alkabanni, W., Alessi-Severini, S., & Leong, C.
- Affiliations
- University of Manitoba (CA)
- Corresponding author
- Brandt, Jaden
- Venue
- Clinical Drug Investigation
- Published
- 2018-04-04
- Volume
- 38
- Issue
- 7
- Pages
- 565-572
- ISSN
- 0114-2402 (ISSN-L)
- 1173-2563
- 1179-1918
- OpenAlex
- W2795474249
- Cited by
- 27
- References
- 29
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 2 · 2022: 5 · 2021: 3 · 2020: 4 · 2019: 3
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Clinical Drug Investigation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- benzodiazepines, medication use, defined daily doses, Z-drugs, prescribing patterns, pharmacovigilance
- MeSH terms
- Zolpidem, Benzodiazepines, Drug Utilization, Humans, Piperazines, Drug Prescriptions, Pyridines, Azabicyclo Compounds, Translational Research, Biomedical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.